A drug's success in the marketplace increasingly depends on the drugmaker's ability to prove value and additional benefit over existing pharmaceuticals, yet many drugmakers still take a blockbuster approach to development, an international survey by Camelot Management Consultants finds. Germany and the U.K. are among the nations linking reimbursement price to additional benefit, which drives pricing elsewhere.

Full Story:
PharmaTimes (U.K.)

Related Summaries